Suggested starting dilutions are as follows: WB: 1:500-1:3000. Suggested fixation for ICC/IF: 3-3.5% PFA with 0.05% saponin treatment. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.
293T , K562 , THP-1 , HL-60 , Neuro 2A , C8D30 , NIH-3T3 , Raw264.7 , C2C12 , NIH-3T3 , JC , BCL-1
Knockdown/Knockout validation was supported by references (PMID:27226592)
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1.36mg/ml(Please refer to the vial label for the specific concentration.)
Amino acids 167-374 of TSG101 protein expressed in E. coli.
Purified by antigen-affinity chromatography.
From tissue culture supernatant
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TSG101-4A10 recognizes TSG101 protein, the product of a recently identified Tumor Susceptibility Gene whose inactivation in mouse fibroblasts results in cell transformation and the ability of those cells to form tumors in nude mice. The TSG101 gene encodes a 46 kDa protein and contains a proline-rich domain and a luecine-zipper motif within a coiled-coil domain near the carboxyl terminus.